成都治静脉曲张要多少费用成都脉管畸形哪治疗好,成都医院看{精索静脉}曲张好,淋巴水肿 成都,四川医院血管炎,成都{静脉炎}该怎么样治疗,成都治疗精索静脉曲张有名的医院,成都海绵状血管瘤手术大约要价格

SAN DIEGO (KGTV) — It’s decision time for the San Diego Padres, who are trying to choose the right candidate to replace fired manager Andy Green.Widespread reports, confirmed by 10News, indicate the Padres have narrowed their search to two very different candidates.The first is 38-year-old Jayce Tingler, who has worked in a variety of coaching and front office roles with the Texas Rangers, but has no Major League managerial experience.RELATED: Padres' Yates wins Baseball Digest's top reliever awardThe second is 67-year-old Ron Washington, who managed the Texas Rangers to back-to-back World Series appearances in 2010 and 2011, before stepping down in 2014. He's currently the 3rd base coach for the Atlanta Braves.The Padres have previously stated a preference for an experienced manager, which could give Washington the edge. But the decision largely rests on the shoulders of general manager A.J. Preller, who is said to be high on Tingler’s ability to communicate with players in English and Spanish along with his understanding of baseball analytics.The timing of the decision remains unknown but both candidates were in San Diego this past week for second interviews with club officials.RELATED: Padres to unveil new 2020 uniforms in NovemberThe team fire Green days before the conclusion of the regular season. Green manned a 274-366 record during his four seasons with the team.Following Green's dismissal, Preller said "the biggest thing I know is we’re better than what we’ve shown," during a media conference. He added that he felt the team needed a "different voice, different direction" moving into the 2020 season."It's a big decision. You don't want to be sitting here in this spot again," Preller told media on hiring a new manager. "It'll be a good process. It'll be detailed." 1808

SAN DIEGO (KGTV) — Infectious disease experts say it may take months before the first doses of a COVID-19 vaccine reach an important population: kids.Some doctors worry it may already be too late to get a vaccine authorized for younger kids before the start of the next school year because of the time it takes to recruit children and conduct a new round of clinical trials.“Our children under 12 years of age are almost certainly going into next school year without a vaccine option available for them,” said Dr. Evan Anderson, a pediatrician at Children’s Healthcare of Atlanta and associate professor at Emory University.Dr. Anderson said such a delay could further impact school reopenings and have resulting consequences on children’s mental health, among other concerns. He said the window is rapidly closing to get a vaccine authorized in time for children older than 12 unless more trials begin immediately.In October, Pfizer tested its vaccine candidate for the first time in 100 kids aged 12 to 15. Moderna is expected to begin testing in that age group in January, according to Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases. However, neither company has announced plans to begin testing their candidates in children under 12.That’s concerning to the American Academy of Pediatrics, which has been calling on vaccine-makers to include children in clinical trials since September. The AAP argues immunization is critical to stemming the pandemic.“We know that children can be infected with COVID-19 and can transmit it to others. To reduce the spread of this virus and control the pandemic as well as for their own safety, it’s crucial that children be included in the national vaccination program, and that vaccines are made available to children as soon as possible,” said Dr. Yvonne Maldonado, chair of the AAP Committee on Infectious Diseases, in another push last month.Although COVID-19 takes a more severe toll on older adults, children make up about 12 percent of the infections in the U.S. and recent studies have shown kids over 10 years old can transmit disease as efficiently as adults, the AAP noted.More than 1.3 million kids had been infected with COVID-19 as of Nov. 26.Experts say it’s important that drug companies test COVID-19 vaccines in children separately from adults.“Kids' immune systems are really different than adults. As any pediatrician will tell you, kids are not just small adults, their immune systems behave really differently,” said Dr. Christian Ramers of Family Health Centers of San Diego.Dr. Ramers said testing is needed to find the right vaccine dose for kids and see if there are any unexpected side effects.But there are challenging logistics in any pediatric trial. Since children’s immune systems change as they grow, vaccine-makers have to separate their trials into several age groups. That means more child volunteers are needed.“I mean it's more challenging, as an investigator myself for research, to enroll a kid into a study because you have to get permission [from parents],” said UC San Francisco infectious disease expert Dr. Peter Chin-Hong.Because parents have to sign off, experts say it can take much longer to enroll enough kids for a study.In a statement to ABC 10News, Pfizer said it is “working actively with regulators on a potential pediatric study plan.”“As we do with all vaccines which are initially studied in adult populations, we are following a careful, stepwise approach as we move down to younger age groups,” said Jerica Pitts, Pfizer’s director of global media relations.“Global regulatory agencies require evaluation of the candidate vaccine in pediatric populations. Moving below 12 years of age will require a new study and potentially a modified formulation or dosing schedule,” she added.Could a vaccine become mandatory at schools?Once a vaccine is approved for kids, a lot of parents are wondering if and when it might become mandatory at California schools.The California Department of Public Health told ABC 10News several things would need to be in place before it would consider making a vaccine mandatory at either schools or child care facilities.The vaccine would need to reviewed and approved by the FDA and recommended for use in children by the federal Advisory Committee on Immunization Practices. The state would also look for a recommendation by the American Academy of Pediatrics, and there would need to be "sufficient vaccine supply to enable access for all children."READ MORE: Will California make the COVID vaccine mandatory at schools? 4602

SAN DIEGO (KGTV) — In some of the most severe cases of COVID-19, doctors are finding it’s not the coronavirus making people critically ill.It’s their own immune system, and a San Diego-based biotech company thinks it has an answer.La Jolla-based INmune Bio announced Tuesday it has FDA approval to begin a Phase 2 clinical trial on its inflammation fighting drug, Quellor.In many of the sickest COVID patients, doctors have noticed their blood is filled with high levels of immune proteins called cytokines. Cytokines act as messengers between cells and the virus can cause them to go haywire, setting off what’s known as a cytokine storm.In a cytokine storm, the body’s immune system starts to attack its own cells and tissues rather than the virus. During the Spanish Flu of 1918, many of the deaths were caused by cytokine storms.“You need to control the cytokine storm to keep patients from getting sick,” said INmune Bio’s CEO Dr. R.J. Tesi.There are several different types of cytokines. A drug undergoing testing in a federal trial with remdesivir targets a cytokine called beta interferon.The San Diego biotech’s drug Quellor suppresses a very specific cytokine called soluble tumor necrosis factor, which Dr. Tesi calls “the master cytokine” because of its role in triggering other immune proteins.Dr. Tesi said this particular cytokine may contribute to another troubling issue with COVID-19: blood clotting.“When they write the history of COVID-19, the clots are going to be the bad guy,” Dr. Tesi said. “These blood clots go off everywhere and they gum up the works. They make it so the lungs can't work. They make it so the kidneys can't work. They make it so the heart is screwed up. Make it so you have strokes.”INmune Bio, which is publicly traded but has just six full-time employees, is hoping its drug can address both the blood clots and the inflammation.The company plans to enroll 366 hospitalized COVID-19 patients for a Phase 2 trial to see if intervention with Quellor can keep people off ventilators and out of the ICU. 2053

SAN DIEGO (KGTV) -- Members of a cannabis church in the Midway District say the San Diego Police Department had no right to raid their church and take seven pounds of marijuana. 185

SAN DIEGO (KGTV) — Mayor Kevin Faulconer and Jewish leaders celebrated the second night of Hanukkah Monday, lighting the second candle of a massive Menorah outside City Hall.As the second night of the Jewish Festival of Lights got underway, Rabbi Zalman Carlebach said it was important for leaders to show their support and celebrate in light of recent anti-Semetic incidents around the U.S. "In light of the current events that are happening around the country, this world could use some more light. America could use some more light," said Rabbi Carlebach.San Diego has numerous Menorah lighting events planned as well as other celebrations throughout the county as Hanukkah continues — running through Dec. 10. Check out where to celebrate in San Diego here. 769